Anti-Müllerian Hormone Is a Marker of Gonadotoxicity in Pre- and Postpubertal Girls Treated for Cancer: A Prospective Study | Zendy

Mark Brougham | Zendy; Patricia M. Crofton | Zendy; Emma Johnson | Zendy; Nancy Evans | Zendy; Richard A. Anderson | Zendy; William H. Wallace | Zendy

Open Access

Anti-Müllerian Hormone Is a Marker of Gonadotoxicity in Pre- and Postpubertal Girls Treated for Cancer: A Prospective Study

Author(s) -

Mark Brougham,

Patricia M. Crofton,

Emma Johnson,

Nancy Evans,

Richard A. Anderson,

William H. Wallace

Publication year - 2012

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2011-3180

Subject(s) - anti müllerian hormone , medicine , prospective cohort study , chemotherapy , fertility preservation , ovarian reserve , hormone , follicle stimulating hormone , gynecology , oncology , premature ovarian failure , endocrinology , physiology , fertility , luteinizing hormone , pregnancy , biology , infertility , population , environmental health , genetics

Cytotoxic treatment may accelerate depletion of the primordial follicle pool, leading to impaired fertility and premature menopause. Assessment of ovarian damage in prepubertal girls is not currently possible, but Anti-Müllerian Hormone (AMH) is a useful marker of ovarian reserve in adults.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research